Biocon Announces U.S. Commercial Debut of Bosaya™ and Aukelso™, Its Denosumab Biosimilars
Biocon Limited, a global innovation-driven biopharmaceutical organization, has announced the commercial launch of two denosumab biosimilars—Bosaya™ and Aukelso™—in the United States, marking a significant expansion of its biosimilars portfolio in one of the world’s largest pharmaceutical markets. These products, referenced as Bosaya and Aukelso, are biosimilar versions of widely used therapies for bone-related conditions and are now available nationwide through specialty pharmacies and healthcare providers.
Both Bosaya™ and Aukelso™ received approval from the U.S. Food and Drug Administration in September 2025, along with an interchangeable designation. This designation is particularly important in the biosimilars landscape, as it allows pharmacists to substitute these products for their reference biologics—Prolia and Xgeva—without requiring direct intervention from the prescribing physician, subject to state-level regulations. This capability is expected to enhance adoption, improve patient access, and contribute to cost savings across the healthcare system.
The launch represents a strategic milestone for Biocon as it continues to strengthen its presence in the U.S. biosimilars market. The company has been steadily building a portfolio of high-quality, affordable biologics, particularly in therapeutic areas such as oncology, immunology, and metabolic diseases. By introducing denosumab biosimilars, Biocon is addressing a critical area of need in bone health, where effective therapies are essential for managing chronic and often debilitating conditions.
Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Limited, emphasized the significance of the launch in advancing the company’s long-term strategy. He noted that the introduction of Bosaya™ and Aukelso™ in the United States reflects Biocon’s commitment to expanding access to high-quality biologic therapies while maintaining affordability. According to Tambe, this milestone highlights the company’s capability as a portfolio development engine and its focus on building a scalable global access platform for life-changing medicines.
Denosumab, the active ingredient in both biosimilars, is a monoclonal antibody that plays a key role in regulating bone resorption. It works by inhibiting RANK ligand (RANKL), a protein involved in the formation, function, and survival of osteoclasts—the cells responsible for bone breakdown. By reducing osteoclast activity, denosumab helps increase bone density and reduce the risk of fractures, making it an essential therapy in several bone-related conditions.
The clinical importance of denosumab-based therapies is reflected in their widespread use and strong market demand. In 2024 alone, denosumab products generated approximately $5 billion in sales in the United States, underscoring the significant need for effective and accessible treatments in this category. The availability of biosimilars like Bosaya™ and Aukelso™ is expected to introduce competitive pricing dynamics, potentially reducing healthcare costs while maintaining therapeutic efficacy.
Bosaya™, the biosimilar to Prolia®, is indicated for conditions such as osteoporosis, a chronic condition characterized by decreased bone mass and increased fracture risk. It is supplied as a 60 mg/mL injection for subcutaneous use in a prefilled syringe, offering a convenient and user-friendly administration format. Osteoporosis is a major public health concern in the United States, affecting an estimated 10 million adults over the age of 50, with an additional 44 million individuals at risk due to low bone density. The disease disproportionately impacts older adults, particularly postmenopausal women, and is associated with significant morbidity, mortality, and healthcare costs.
The burden of osteoporosis is substantial, with statistics indicating that one in two women and up to one in four men over the age of 50 will experience a bone fracture during their lifetime due to the condition. These fractures, particularly those involving the hip or spine, can lead to long-term disability, reduced quality of life, and increased mortality risk. By providing a more affordable biosimilar option, Biocon aims to improve treatment accessibility and encourage earlier intervention, which is critical for preventing fractures and preserving bone health.
Aukelso™, the biosimilar to Xgeva®, is designed to address bone complications associated with cancer, including bone metastases and other skeletal-related events. It is available as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial. Bone metastases occur when cancer cells spread from their original site to the bones, leading to pain, fractures, and other complications that can significantly impact patient quality of life.
In the United States, more than 330,000 patients are affected by bone metastases each year, making it a common and serious complication of advanced cancers such as breast, prostate, and lung cancer. Managing these complications is a critical component of oncology care, as skeletal-related events can increase healthcare utilization and negatively affect patient outcomes. The introduction of Aukelso™ provides an additional therapeutic option for clinicians seeking to manage these complex cases effectively.
Another condition addressed by denosumab therapies is Giant cell tumor of bone (GCTB), a rare but locally aggressive tumor that primarily affects young adults. Although noncancerous, GCTB can cause significant morbidity, including severe pain, bone destruction, and functional impairment. Treatment options for this condition are limited, and denosumab has emerged as an important therapy for managing disease progression and improving patient outcomes.
The launch of Bosaya™ and Aukelso™ also reflects broader trends in the pharmaceutical industry, where biosimilars are playing an increasingly important role in expanding access to biologic therapies. By offering comparable efficacy and safety to their reference products at a lower cost, biosimilars have the potential to alleviate financial pressures on healthcare systems while ensuring that patients receive high-quality care.
Biocon’s entry into the denosumab biosimilars market further strengthens its position as a global leader in biosimilars development and commercialization. The company has invested heavily in research, manufacturing, and regulatory capabilities to support the development of complex biologics, enabling it to compete effectively in highly regulated markets such as the United States.
In summary, the U.S. launch of Bosaya™ and Aukelso™ represents a major milestone for Biocon Limited and a meaningful advancement for patients requiring treatment for osteoporosis, cancer-related bone complications, and rare bone tumors. By combining clinical efficacy with improved affordability and accessibility, these biosimilars are poised to make a significant impact on patient care. As the demand for cost-effective biologic therapies continues to grow, initiatives like this underscore the critical role of biosimilars in shaping the future of healthcare delivery.
About BOSAYA 1 and AUKELSO 2 :
Denosumab is a human monoclonal antibody that targets and binds to Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). RANKL is essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By blocking RANKL, denosumab reduces bone breakdown, increasing bone mass and strength.
About BOSAYA (denosumab-kyqq)
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE
See full prescribing information for complete boxed warning.
- Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia.
Prior to initiating BOSAYA in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with BOSAYA in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD.
Source Link:https://www.businesswire.com/
